Payment overview · 2025
General Payments
$1,505.00
26 reported records · 17 companies
Healthcare provider profile · identity verified
Nathan Laufer, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · PHOENIX, AZ · NPI 1871587048
Verified facts
What the public records show
CMS Open Payments records show Nathan Laufer, MD received $1,505.00 in general payments during 2025 across 26 reported records.
Edwards Lifesciences Corporation accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $449.18 | 29.9% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $295.09 | 19.6% | 4 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $149.99 | 10.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $116.20 | 7.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $100.27 | 6.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $72.33 | 4.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $50.21 | 3.3% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $45.35 | 3.0% | 2 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $44.38 | 3.0% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $25.28 | 1.7% | 1 | 2025 |
| CMP Pharma, Inc. | Unresolved — no canonical attribution shown | $24.48 | 1.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$24.36 | 1.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.25 | 1.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.36 | 1.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.28 | 1.5% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $21.87 | 1.4% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $18.12 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,505.00 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $410.96 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $161.01 | 2 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $149.99 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $116.20 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $102.80 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $100.27 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $72.33 | 3 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $50.21 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $45.35 | 2 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $44.38 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $44.38 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $38.22 | 1 | 2025 |
Source payment records
|
|||||
| LithoVue Empower Normalized: lithovue empower |
Device | Boston Scientific Corporation | $31.28 | 1 | 2025 |
Source payment records
|
|||||
| Atorvaliq Normalized: atorvaliq |
Drug | CMP Pharma, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| carospir Normalized: carospir |
Drug | CMP Pharma, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| liqrev Normalized: liqrev |
Drug | CMP Pharma, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| norliqva Normalized: norliqva |
Drug | CMP Pharma, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| tadliq Normalized: tadliq |
Drug | CMP Pharma, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $18.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 978 | 308 |
| Clopidogrel | Clopidogrel Bisulfate | 590 | 201 |
| Amlodipine Besylate | Amlodipine Besylate | 511 | 176 |
| Ezetimibe | Ezetimibe | 493 | 171 |
| Eliquis | Apixaban | 482 | 133 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 431 | 160 |
| Losartan Potassium | Losartan Potassium | 428 | 140 |
| Lisinopril | Lisinopril | 382 | 126 |
| Atenolol | Atenolol | 372 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 318 | 113 |
| Flecainide Acetate | Flecainide Acetate | 245 | 82 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 202 | 63 |
| Furosemide | Furosemide | 202 | 69 |
| Carvedilol | Carvedilol | 184 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 59 |
| Repatha Sureclick | Evolocumab | 150 | 29 |
| Warfarin Sodium | Warfarin Sodium | 142 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 48 |
| Digoxin | Digoxin | 111 | 34 |
| Xarelto | Rivaroxaban | 96 | 36 |
| Simvastatin | Simvastatin | 91 | 30 |
| Verapamil Er | Verapamil Hcl | 85 | 20 |
| Potassium Chloride | Potassium Chloride | 83 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 32 |
| Amiodarone Hcl | Amiodarone Hcl | 72 | 31 |
| Clonidine Hcl | Clonidine Hcl | 67 | 27 |
| Spironolactone | Spironolactone | 62 | 23 |
| Lovastatin | Lovastatin | 61 | 20 |
| Ranolazine Er | Ranolazine | 60 | 20 |
| Sotalol | Sotalol Hcl | 42 | 12 |
| Nitroglycerin | Nitroglycerin | 41 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 13 |
| Entresto | Sacubitril/Valsartan | 34 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | 11 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Cartia Xt | Diltiazem Hcl | 15 | suppressed |
| Sotalol Af | Sotalol Hcl | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,505.00 · 26 records | Edwards Lifesciences Corporation | Assure WCD, Atorvaliq, CARDIOMEMS, Cleerly Ischemia, Cleerly Labs, ENDURANT IIS, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, Hillrom - Carnation Ambulatory Monitor, INSPIRE, JARDIANCE, Kerendia, LEQVIO, LUX-Dx Insertable Cardiac Monitor, Leqembi, LifeVest, LithoVue Empower, SAPIEN 3 Ultra RESILIA, WATCHMAN FLX, WatchPATONE, Wegovy, carospir, liqrev, norliqva, tadliq | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error